Skip to main content
Premium Trial:

Request an Annual Quote

Knome Raises $5.8M

NEW YORK (GenomeWeb News) – Knome has raised almost $5.8 million toward a targeted goal of $6.3 million, the bioinformatics firm said recently in a regulatory document.

The company did not respond to a request for comment. It did not say in its Form D filed with the US Securities and Exchange Commission who the investors are or how the funds would be used.

The securities offered were in the form of debt.

Based in Cambridge, Mass., Knome provides human genome interpretation software and services. In June, it said that it would offer Omixon's targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines. That followed a deal with Real Time Genomics to integrate the Real Time Genomics Variant platform into every shipment of the knoSys 100 interpretation system.

In August 2011, Knome said in an SEC document that it raised $5 million in a financing round that targeted $20 million.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.